Evidence map›Paper›PMID 30213530›Full record

ArticleTranslational research : the journal of laboratory and clinical medicine2019

Toward genome editing in X-linked RP-development of a mouse model with specific treatment relevant features.

J Schlegel, J Hoffmann, D Röll, B Müller, S Günther, W Zhang, A Janise, C Vössing, B Fühler, J Neidhardt and 3 more

Open access · greenAbstract read
In one paragraph

Article in Translational research : the journal of laboratory and clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Genome Editing for Rare Diseases.Current stem cell reports · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

J SchlegelDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
J HoffmannDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
D RöllDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
B MüllerDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
S GüntherMax-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
W ZhangDepartment of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts.
A JaniseDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
C VössingHuman Genetics, Faculty of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany.
B FühlerDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
J NeidhardtHuman Genetics, Faculty of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany; Research Center Neurosensory Science, University Oldenburg, Oldenburg, Germany.
H KhannaDepartment of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts.
B LorenzDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
K StiegerDepartment of Ophthalmology, Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany. Electronic address: Knut.Stieger@uniklinikum-giessen.de.
Justus-Liebig-Universität Gießen · DECarl von Ossietzky Universität Oldenburg · DEUniversity of Massachusetts Chan Medical School · USMax Planck Institute for Heart and Lung Research · DE

Funding

Function of Ciliary Disease Protein Retinitis Pigmentosa GTPase Regulator (RPGR)R01EY022372 · NEI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PAZOUR, GREGORY J · 2012 to 2020
$3.7M
NEI NIH HHS R01 EY022372
6 · The paper itself

Abstract

Genome editing represents a powerful tool to treat inherited disorders. Highly specific endonucleases induce a DNA double strand break near the mutant site, which is subsequently repaired by cellular DNA repair mechanisms that involve the presence of a wild type template DNA. In vivo applications of this strategy are still rare, in part due to the absence of appropriate animal models carrying human disease mutations and knowledge of the efficient targeting of endonucleases. Here we report the generation and characterization of a new mouse model for X-linked retinitis pigmentosa (XLRP) carrying a point mutation in the mutational hotspot exon ORF15 of the RPGR gene as well as a recognition site for the homing endonuclease I-SceI. Presence of the genomic modifications was verified at the RNA and protein levels. The mutant protein was observed at low levels. Optical coherence tomography studies revealed a slowly progressive retinal degeneration with photoreceptor loss starting at 9 months of age, paralleling the onset of functional deficits as seen in the electroretinogram. Early changes to the outer retinal bands can be used as biomarker during treatment applications. We further show for the first time efficient targeting using the I-SceI enzyme at the genomic locus in a proof of concept in photoreceptors following adeno-associated virus mediated gene transfer in vivo. Taken together, our studies not only provide a human-XLRP disease model but also act as a platform to design genome editing technology for retinal degenerative diseases using the currently available endonucleases.

Indexed as

Disease Models, AnimalGene EditingAnimalsCarrier ProteinsEye ProteinsHumansMiceMice, KnockoutMutationRetinitis PigmentosaReverse Transcriptase Polymerase Chain ReactionRNA, MessengerCarrier ProteinsEye ProteinsRNA, MessengerRPGR protein, mouse

Identifiers

PMID30213530
PMCPMC6294733
OpenAlexW2888335163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.